[Skip to Navigation]
Sign In
JAMA Oncology Clinical Evidence Synopsis
December 2016

Chemotherapy for Advanced Non–Small-Cell Lung Cancer in Elderly Patients

Author Affiliations
  • 1Medical Oncology, Hospital São Carlos, Fortaleza, Brazil
  • 2Medical Oncology, Beneficência Portuguesa de São Paulo, São Paulo, Brazil
  • 3Brazilian Cochrane Centre, Centro de Saúde Baseado em Evidência e Avaliação Tecnológica em Saúde, São Paulo, Brazil
JAMA Oncol. 2016;2(12):1645-1646. doi:10.1001/jamaoncol.2016.2050

Clinical Question  Do patients above 70 years of age with newly diagnosed advanced non–small-cell lung cancer benefit from platinum-based combination or should they receive non-platinum agents either as single-agent or in combination?

Bottom Line  For fit elderly patients platinum-based combination is associated with better overall survival, progression-free survival, and objective response rate, however this improvement should be counter balanced against the higher risk of major adverse events (AE).

Add or change institution